The role of the tyrosine kinase inhibitor STI571 in the treatment of cancer

Current Cancer Drug Targets

Volumn 1, Issue 1, 2001, Pages 49-57

  O'Dwyer, Michael E ^a   Druker, Brian J ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; ENZYME INHIBITOR; IMATINIB; PIPERAZINE DERIVATIVE; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE;

ANIMAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG DESIGN; DRUG SCREENING; ENZYMOLOGY; GENETICS; HUMAN; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; DRUG DESIGN; DRUG EVALUATION; ENZYME INHIBITORS; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOID, CHRONIC; PIPERAZINES; PROTEIN-TYROSINE KINASES; PYRIMIDINES;

EID: 0035342380     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568009013334250     Document Type: Article

References (44)

1. Sawyers, C. L. Chronic Myeloid Leukemia. N. Engl. J. Med. 1999, 340, 1330-1340.
2. Silver. R. T.; Woolf, S. H.; Hehlmann, R. Appelbaum, F. R.; Anderson, J.; Bennett, C. Goldman, J. M.; Guilhot, F.; Kantarjian, H. M. Lichtin, A. E.; Talpaz, M.; Tura, S. An EvidenceBased Analysis of the Effect of Busulfan, Hydroxyurea, Interferon, and Allogeneic Bone Marrow Transplantation in Treating the Chronic Phase of Chronic Myeloid Leukemia: Developed for the American Society of Hematology [see commentsJ. Blood 1999, 94, 1517-1536
3. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon alfa-2a as Compared with Conventional Chemotherapy for the Teatment of Chronic Myeloid Leukemia. N. Engl. J. Med. 1994,330, 820-825
4. Myeloid Leukemia Trialists1 Collaborative Group. Interferon alfa versus Chemotherapy for Chronic Myeloid Leukemia: A Meta-analysis of Seven Randomized Trials. J. Nail. Cancer Inst. 1997, 89, 1616-1620.
5. Guilhot, F.; Chastang, C.; Michallet, M.; Guerci, A.; Harousseau, J. L.; Maloisel, F., Bouabdallah, R.; Guyotat, D.; Cheron, N.; Nicolini, F.; Abgrall, J. F.; Tanzer, J. Interferon alfa-2b Combined with Cytarabine Versus Interferon Alone in Chronic Myelogenous Leukemia. French Chronic Myeloid Leukemia Study Group [see commentsJ. N. Engl. J. Med. 1997, 337, 223-229.
6. Nowell, P. C.; Hungerford, D. A. A Minute Chromosome in Human Chronic Granulocytic Leukemia. Science 1960, 732, 1497-1501.
7. Rowley, J. D. A new Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia Identified by Quinacrine Fluorescence and Giemsa Staining. Nature 1973,243, 290-293.
8. Shtivelman, E.; Lifshitz, B.; Gale, R. P,; Canaani, E. Fused Transcript of abl and bcr Genes in Chronic Myelogenous Leukaemia. Nature 1985, 375, 550-554.
9. Lugo, T. G,; Pendergast, A. M,; Muller, A. J,; Witte, O. N. Tyrosine Kinase Activity and Transformation Potency of bcr-abl Oncogene Products. Science 1990, 247, 1079-1082.
10. Daley, G. Q,; Van Etten, R. A,; Baltimore, D. Induction of Chronic Myelogenous Leukemia in Mice by the p210bcr/abl gene of the Philadelphia Chromosome. Science 1990, 247, 824-830.
11. Heisterkamp, N.; Jenster, G.; ten Hoeve, J.; Zovich, D.; Pattengale, P. K.; Groffen, J. Acute Leukaemia in bcr/abl Transgenic Mice. Nature 1990,344, 251-253.
12. Deininger, M. W.; Goldman, J. M.; Melo, J. V. The Molecular Biology of Chronic Myeloid Leukemia. Blood2000, 96, 3343-56.
13. Yaish, P.; Gazit, A.; Gilon, C.; Levitzki, A. Blocking of EGF-Dependent Cell Proliferation by EOF Receptor Kinase Inhibitors. Science 1988, 242, 933-935.
14. Druker, B. J.; Lydon, N. B. Lessons Learned from the Development of an abl Tyrosine Kinase Inhibitor for Chronic Myelogenous Leukemia. J. Clin. Invest. 2000, 705, 3-7.
15. Schindler, T.; Bornmann, W.; Pellicena, P.; Miller, W. T.; Clarkson, B.; Kuriyan, J. Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase. Science 2000,289, 1938-42.
16. Druker, B. J.; Tamura, S.; Buchdunger, E.; Ohno, S.; Segal, G. M.; Fanning, S.; Zimmermann, J.; Lydon, N. B. Effects of a Selective Inhibitor of the Abi Tyrosine Kinase on the Growth of Bcr-Abl Positive Cells. Nat. Med. 1996, 2, 561-566.
17. Deininger, M. W.; Goldman, J. M.; Lydon, N.; Melo, J. V. The Tyrosine Kinase Inhibitor CGP57148B Selectively linhibits the Growth of BCR-ABL-Positive Cells. Blood 1997, 90, 3691-3698.
18. Kasper, B.; Fruehauf, S.; Schiedlmeier, B.; Buchdunger, E.; Ho, A. D.; Zeller, W. J. Favorable Therapeutic Index of a p210(BCR-ABL)-Specific Tyrosine Kinase Inhibitor: Activity on LineageCommitted and Primitive Chronic Myelogenous Leukemia Progenitors. Cancer Chemother. Pharmacol. 1999, 44, 433-438.
19. Carroll, M.; Ohno-Jones, S.; Tamura, S.; Buchdunger, E.; Zimmermann, J.; Lydon, N. B.; Gilliland, D. G.; Druker, B. J. CGP 57148, a Tyrosine Kinase Inhibitor, Inhibits the Growth of Cells Expressing BCR-ABL, TEL-ABL, and TELPDGFR Fusion Proteins. Blood 1997, 90, 4947-4952.
20. Beran, M.; Cao, X.; Estrov, Z.; Jeha, S.; Jin, G.; O'Brien, S.; Talpaz, M.; Arlinghaus, R. B.; Lydon, N. B.; Kantarjian, H. Selective Inhibition of Cell Proliferation and BCR-ABL Phosphorylation in Acute Lymphoblastic Leukemia Cells Expressing Mr 190,000 BCR-ABL Protein by a Tyrosine Kinase Inhibitor (CGP-57148). Clin. Cancer Res. 1998, 4, 1661-1672.
21. le Coutre, P.; Mologni, L.; Cleris L; Marchesi, E.; Buchdunger, E.; Giardini, R.; Formelli, F.; Gambacorti-Passerini, C. In Vivo Eradication of Human BCR/ABL-Positive Leukemia Cells with an ABL Kinase Inhibitor [see commentsJ. J. Nail. Cancer Inst. 1999,97, 163-168.
22. Druker, B. J.; Talpaz, M.; Resta, D.; Peng, B.; Buchdunger, E.; Ford, J.; Sawyers, C. L. Clinical Efficacy and Safety of an ABL Specific Tyrosine Kinase Inhibitor as Targeted Therapy for Chronic Myelogenous Leukemia. Blood Suppl. 1999.
23. Druker, B. J.; Talpaz, M.; Resta, D. J.; Peng, B.; Buchdunger, E.; Ford, J. M.; Lydon, N. B.; Kantarjian, H.; Capdeville, R.; Ohno-Jones, S.; Sawyers, C. L. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 2001,344, 1057.
24. Talpaz, M.; Sawyers, C. L.; Kantarjian, H.; Resta, D.; Fernandes, Reese S, Ford, J.; Druker, B.J. Activity of an Abl Specific Tyrosine Kinase Inhibitor in Patients with Bcr-Abl Positive Acute Leukemias, Including Chronic Myelogenous Leukemia in Blast Crisis. Proc. Am. Soc. Clin. Ocol. 2000,19, 4a.
25. Druker, B. J.; Sawyers, C. L.; Kantarjian, H.; Resta, D. J.; Fernandas Reese, S.; Ford, J. M.; Capdeville, R.; Talpaz, M. Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome. N. Engl. J. Med. 2001, in press.
26. Peng, B., Hayes, M., Druker, B.Talpaz, M.; Sawyers, C.; Resta, D.; Ford, J.; Man, A. Clinical Pharmacokinetics and Pharmacodynamics of STI571 in a Phase 1 Trial in Chronic Myelogenous Leukemia (CML) Patients. Proc. Am. Assoc. Cancer Res. 2000, 41, Abstr. #3468.
27. Kantarajian, H.; Sawyers, C.; Hochhaus, A.; Guilhot, F.; Schiffer, C.; Resta, D.; Capdeville, R.; Druker, B. Phase II Study of STI571, a Tyrosine Kinase Inhibitor, in Patients with Resistant or Refractory Philadelphia Chromosome-Positive Chronic Myeloid Leukemia. Blood2000, 96, 470a.
28. Talpaz, M.; Silver, R. T.; Druker, B.; Paquette, R.; Goldman, J. M.; Reese, S. F.; Capdeville, R. A Phase II Study of STI571 in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Accelerated Phase. Blood 2000, 96, 469a.
29. Sawyers, C.; Hochhaus, A.; Feldman, E.; Goldman, J. M.; Miller, C.; Ben-Am, M.; Capdeville, R.; Druker, B. A Phase II Study to Determine the Safety and Anti-Leukemic Effects of STI571 in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Myeloid Blast Crisis. Blood 2000, 96, 503a.
30. le Coutre, P.; Tassi, E.; Varella-Garcia, M.; Bami, R.; Mologni, L.; Cabrita, G.; Marchesi, E.; Supino, R.; Gambacorti-Passerini, C. Induction of Resistance to the Abelson Inhibitor STI571 in Human Leukemic Cells Through Gene Amplification. Blood 2000, 95, 1758-1766.
31. Mahon, F. X.; Deininger, M. W.; Schultheis, B.; Chabrol, J.; Reiffers, J.; Goldman, J. M.; Mélo, J. V. Selection and Characterization of BCR-ABL Positive Cell Lines with Differential Sensitivity to the Tyrosine Kinase Inhibitor STI571: Diverse Mechanisms of Resistance. Blood 2000, 96, 10701079.
32. Weisberg, E.; Griffin, J. D. Mechanism of Resistance to the ABL Tyrosine Kinase Inhibitor STI571 in BCR/ABL-Transformed Hematopoietic Cell Lines. 5/oorf 2000, P5, 3498-3505.
33. Knight, Z. A. Another Possible Mechanism of Resistance to STI571. Blood 2000, 96, 4003-4005.
34. Oda, T.; Heaney, C.; Hagopian, J. R.; Okuda, K.; Griffin, J. D.; Druker, B. J. Crkl is the Major Tyrosine-Phosphorylated Protein in Neutrophils from Patients with Chronic Myelogenous Leukemia. J. Biol. Chem. 1994, 269, 22925-22928.
35. Gorre M, Banks K, Hsu NC, Monsour M, Rao NP, Ford JM, Paquette R, Sawyers CL. Relapse in Ph+ Leukemia Patients with an Abl-Specific Kinase Inhibitor is Associated with Reactivation of Bcr-Abl. Blood 2000, 96, 470a.
36. Thiesing, J. T.; Ohno-Jones, S.; Kolibaba, K. S.; Druker, B. J. Efficacy of STI571, an Abl Tyrosine Kinase Inhibitor, in Conjunction with Other Antileukemic Agents Against Bcr-Abl-Positive Cells. Blood2000, 96, 3195-3199.
37. Fang, G.; Kim, C. N.; Perkins, C. L.; Ramadevi, N.; Winton, E.; Wittmanri, Bhalla, K. N. CGP57148B (STI571) Induces Differentiation and Apoptosis and Sensitizes Bcr-Abl Positive Human Leukemia Cells to Apoptosis due to Antileukemic Drugs. Blood 2000, 96, 2246-2253.
38. Peters, D. G.; Hoover, R. R.; Yoh, E. Y.; Zhang, H.; Mahon, F. X.; Melo, J. V.; Kirschmeier, P.; Bishop, W. R.; Daley, G. Q. Activity of the Farnesyl Transferase Inhibitor SCH66336 Against Bcr-Abl Induced Murine Leukemia, STI571 Resistant CML Cell Lines, and Primary Cells from CML Patients. Blood 2000, 96, 510a.
39. Heinrich, M. C.; Griffith, D. J.; Druker, B. J.; Wait, C. L.; Ott, K. A.; Zigler, A. J. Inhibition of c-kit Receptor Tyrosine Kinase Activity by STI 571, a Selective Tyrosine Kinase Inhibitor. Blood 2000, 96, 925-932.
40. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, Tunio GM, Matsuzawa Y, Kanakura Y, Shinomura Y, Kitamura Y: Gain-ofFunction Mutations of c-kit in Human Gastrointestinal Stromal Tumors. Science 1998, 279, 577-580.
41. Krystal, G. W.; Honsawek, S.; Litz, J.; Buchdunger, E. The Selective Tyrosine Kinase Inhibitor STI571 Inhibits Small Cell Lung Cancer Growth. Clin. Cancer Res. 2000, 6, 3319-3326.
42. Wang, W. L.; Healy, M. E.; Sattler, M.; Verma, S.; Lin, J.; Maulik, G.; Stiles, C. D.; Griffin, J. D.; Johnson, B. E.; Salgia, R. Growth Inhibition and Modulation of Kinase Pathways of Small Cell Lung Cancer Cell Lines by the Novel Tyrosine Kinase Inhibitor STI 571. Oncogene 2000,19, 3521-3528.
43. Kilic, T.; Alberta, J. A.; Zdunek, P. R.; Acar, M.; lannarelli, P.; O'Reilly, T.; Buchdunger, E.; Black, P. M., Stiles, C. D. Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. Cancer Res. 2000, 60,5143-5150.
44. Kolibaba, K. S.; Druker, B. J. Protein Tyrosine Kinases and Cancer. Biochim. Biophys. Acta 1997, 1333, F217-248.